# Cytokines, Signaling and Epigenetic Mechanisms: Shaping the Acute Lymphoblastic Leukemia Microenvironment

## TL;DR

This review explores how cytokines, signaling pathways, and epigenetic changes shape the environment in which acute lymphoblastic leukemia develops and resists treatment.

## Contribution

The paper provides a comprehensive analysis of the interplay between cytokines, signaling pathways, and epigenetics in the ALL microenvironment.

## Key findings

- Cytokines like IL-6, TNF-α, and CXCL12 are key mediators of leukemia niche remodeling.
- Signaling pathways such as Wnt/β-catenin and JAK/STAT are functionally interconnected with the tumor microenvironment.
- Epigenetic mechanisms regulate leukemia's dependence on stromal and inflammatory signals.

## Abstract

Acute Lymphoblastic Leukemia (ALL) is a heterogeneous hematological malignancy in which disease progression and response to therapy are influenced by a complex network of molecular alterations, interactions with the bone marrow microenvironment, and epigenetic modulation mechanisms. Crosstalk between oncogenic, inflammatory, and immunoregulatory signaling pathways, together with epigenetic modifications, contributes to the maintenance of leukemic survival and the development of therapeutic resistance. This review analyzes the role of cytokines and chemokines such as IL-6, TNF-α, and CXCL12, which act as biological biomarkers and key mediators of leukemia niche remodeling, and the main signaling pathways involved in ALL, such as Wnt/β-catenin, JAK/STAT, PI3K/AKT/mTOR, Notch, and BCR, highlighting their functional interconnection with the tumor microenvironment. The role of epigenetics in modulating the dialogue between leukemia cells and stromal components is also discussed. Epigenetic programs govern leukemia’s dependence on stromal support, inflammatory and niche-derived signals, as well as the microenvironment signaling pathways. Overall, targeting leukemia-niche interactions is a crucial strategy for improving outcomes in ALL and to identify potential molecular vulnerabilities, also for developing new therapeutic approaches for the treatment of the disease.